Navigation Links
Neurologix Completes Additional $7 Million Financing
Date:12/6/2010

ceive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2009 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.Contact: NeurologixMarc Panoff, 201-592-6451 Chief Financial Officer marcpanoff@neurologix.net
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... -- Stryker Corporation,s Orthopaedics Division, the Official Joint Replacement Products of ... of joint health to golf fans in its home state ... The Barclays.  The company,s fan destination – "The Stryker Mobility ... 17 th fairway at the Ridgewood Country Club in ... st .    At The Barclays, Stryker will ...
    (Date:8/19/2014)... N.Y. , Aug. 19, 2014  Regeneron Pharmaceuticals, ... following investor conferences: , Sanofi and Regeneron will host ... Eastern Time on Tuesday, September 2, 2014 , ... on Wednesday, September 3, 2014 , Citi,s 9 ... Time on Thursday, September 4, 2014 , Morgan ...
    (Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
    Breaking Medicine Technology:Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
    ... Oct. 13, 2011 K-V Pharmaceutical Company (the ... of Obstetricians and Gynecologists (ACOG) and Society for ... that ensures healthcare providers, patients, and the payer ... information update emphasizes that previous ACOG and SMFM ...
    ... 13, 2011 IVD Technology , ... diagnostics technologies including research, development, and manufacturing, today announced ... emerging trend in the industry – ... (CONTACT:   http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ) The featured speaker ...
    Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 2Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 3
    (Date:8/20/2014)... they often have difficulty falling asleep and staying asleep, ... In individuals with Alzheimer,s disease, this common and troubling ... leading to nighttime confusion and wandering. , Now, a ... Center (BIDMC) and the University of Toronto/Sunnybrook Health Sciences ... age. Reported online today in the journal Brain ...
    (Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... will honor the 2014 Emmy Award Nominees and Presenters at ... place on August 22nd and 23rd in Beverly Hills from ... enjoy gifts, refreshments and music by DJ Morgan Hildebrand. , ... charity fundraising and will feature several charities at the lounge. ...
    (Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
    (Date:8/20/2014)... York (PRWEB) August 20, 2014 Over 31 ... Global Bureau of Disease, low back pain is the single ... most common reasons for missed work. Americans spend at least ... pain. , Most cases of back pain are not due ... (non-organic) origin. , For example, Pete, a busy accountant, had ...
    (Date:8/19/2014)... (PRWEB) August 20, 2014 As moms and ... for themselves to return to the normal routine of dropping ... in tow, Kristen Yarker, MSc, RD encourages them to ... their kids’ snack time. , Yarker explains, “Kids have ... nutrients. Instead of giving them junk food handouts, use snack ...
    Breaking Medicine News(10 mins):Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
    ... of stroke victims suffer vision difficulties due to cortical ... holds immense promise for patients suffering partial impairment of ... medical instrument has been devised that is capable of ... This could indeed be the light at the end ...
    ... gene expression in the mouse brain is considered a scientific ... or 57.7 million people//. , ,The Allen Institute ... The Allen Institute was started in 2003 and the Atlas ... given by Microsoft co-founder Paul G. Allen funded both. ...
    ... Sufferers,Television personality Angela Rippon is fronting a new DVD ... Chronic Obstructive Pulmonary Disease (COPD). The DVD called Move ... ,COPD includes a range of lung diseases like chronic ... make a difference to the lives of people living ...
    ... HIV/AIDS is a major hindrance in controlling the fast-spreading disease ... discrimination are indeed problem areas in tackling HIV/AIDS in India," ... for HIV/AIDS in Asia and the Pacific. ,"There ... lots needs to be done to make it (the disease) ...
    ... for the cartoon man, Popeye, who simply preens at the ... spinach and an icon that little kids swear by, what ... who still boasts of a perfect vision without the help ... with a novel eye device are trying to understand the ...
    ... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
    Cached Medicine News:Health News:Allen Brain Atlas – a 3-D gene map of brai 2Health News:Remove Stigma to Defeat HIV/AIDS in India, says UN Envoy 2Health News:Go Green with Popeye: Learn why his eyes pop out for spinach! 2
    ... Implant System provides todays surgeon with ... head replacement. Modular stem and ... while minimizing ligamentous and soft tissue ... guide assists in both the radial ...
    ... modular radial head system employs the advantages ... to create the next generation of modular ... part, modular design, the implant system offers ... the patients anatomy. In addition, the capability ...
    All Padgett bipolar forceps are foot activated. The standard-type connectors fit generators utilizing the standard receivers for small "banana" inserts. All Padgett bipolar foot activated forceps an...
    For connection to the bipolar output of electrosurgical generators....
    Medicine Products: